October 23, 2025 – ecancer published its 10th annual ESMO Congress recap with Dr. Bishal Gyawali. In this video, Dr. Gyawali shares insights on the most noteworthy items to come out of the 2025 ESMO Congress in Berlin, Germany.
Highlights include:
- 5-year follow up results from the POSITIVE trial (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer)
- Primary OS results from the monarchE trial (adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer)
- 5-year outcomes from NATALEE (adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer)
- Phase II, randomized open-labelled study evaluating low-dose pembrolizumab + neoadjuvant chemotherapy in triple negative breast cancer (TNBC)
- DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)
- Interim analysis of DESTINY-Breast05: Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer with residual invasive disease after neoadjuvant therapy
- Initial results from VIKTORIA-1: Giredestrant, an oral selective oestrogen receptor antagonist and degrader, + everolimus in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial and Gedatolisib + fulvestrant ± palbociclib vs fulvestrant in patients with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC)
- Initial results from ASCENT-03: A randomized phase III study of sacituzumab govitecan vs chemotherapy in patients with previously untreated advanced TNBC who are unable to receive PD-(L)1 inhibitors.
- Initial results from TROPION-Breast02: first-line datopotamab deruxtecan vs chemotherapy in patients with locally recurrent inoperable or mTNBC for whom immunotherapy was not an option
- KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible
- ALBAN: A phase III, randomized, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin vs BCG alone in BCG-naïve high-risk, non-muscle-invasive bladder cancer.
- Final analysis of the phase III, open-label, randomised POTOMAC trial: Durvalumab in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC)
- Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
- EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer
- Open-label, phase III, randomized trial, PAULIEN: Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%:
- Results from the randomized, multi-center phase III trial, OptiTROP-Lung04: Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs
- Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression
- IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
- Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG): ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer
- Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric / gastroesophageal junction adenocarcinoma
- Primary overall survival (OS) analysis from the randomized, open-label, phase III trial STELLAR-303: Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
- Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma
- Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma
- Final results of RAR-IMMUNE: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype
Dr. Bishal Gyawali 
Leave a comment